Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease

Journal of Clinical Virology

Volumn 50, Issue 1, 2011, Pages 31-36

  Sankaran Walters, Sumathi ^a   Ransibrahmanakul, Kanat ^b   Grishina, Irina ^a   Hung, Jason ^a   Martinez, Enrique ^a   Prindiville, Thomas ^b   Dandekar, Satya ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epstein Barr virus; Inflammatory bowel disease; Mucosa; Refractory disease; Viral load

Indexed keywords

VIRUS DNA;

ARTICLE; B LYMPHOCYTE; COLON MUCOSA; CONTROLLED STUDY; COPY NUMBER VARIATION; CROSS-SECTIONAL STUDY; ENTERITIS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE LOCATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; CELL PROLIFERATION; COLON; CROSS-SECTIONAL STUDIES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MUCOUS MEMBRANE; RETROSPECTIVE STUDIES; VIRAL LOAD; VIRUS REPLICATION; YOUNG ADULT;

EID: 78650930211     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.09.011     Document Type: Article

References (38)

1. Himmel M.E., Hardenberg G., Piccirillo C.A., Steiner T.S., Levings M.K. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology 2008, 125(October (2)):145-153.
2. Macfarlane S., Steed H., Macfarlane G.T. Intestinal bacteria and inflammatory bowel disease. Crit Rev Clin Lab Sci 2009, 46(1):25-54.
3. Niess J.H. Role of mucosal dendritic cells in inflammatory bowel disease. World J Gastroenterol 2008, 14(September (33)):5138-5148.
4. Shih D.Q., Targan S.R., McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep 2008, 10(December (6)):568-575.
5. Prindiville T.P., Sheikh R.A., Cohen S.H., Tang Y.J., Cantrell M.C., Silva J. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg Infect Dis 2000, 6(March-April (2)):171-174.
6. Anton P.A. Stress and mind-body impact on the course of inflammatory bowel diseases. Semin Gastrointest Dis 1999, 10(January (1)):14-19.
7. Mutlu E.A., Farhadi A., Keshavarzian A. New developments in the treatment of inflammatory bowel disease. Expert Opin Investig Drugs 2002, 11(March (3)):365-385.
8. Caviglia R., Boskoski I., Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf 2008, 7(September (5)):617-632.
9. Louis E., Belaiche J., Reenaers C. Are we giving biologics too much time? When should we stop treatment?. World J Gastroenterol 2008, 14(September (36)):5528-5531.
10. Sandborn W.J. Current directions in IBD therapy: what goals are feasible with biological modifiers?. Gastroenterology 2008, 135(November (5)):1442-1447.
11. Shteyer E., Wilschanski M. Novel therapeutic modalities in pediatric inflammatory bowel disease. Isr Med Assoc J 2008, 10(November (11)):816-820.
12. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(May (19)):2275-2285.
13. Shepela C. The safety of biologic agents in the treatment of inflammatory bowel disease. Minn Med 2008, 91(June (6)):42-45.
14. Decker L.L., Klaman L.D., Thorley-Lawson D.A. Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J Virol 1996, 70(May (5)):3286-3289.
15. Miller G. The switch between EBV latency and replication. Yale J Biol Med 1989, 62(March-April (2)):205-213.
16. Lidar M., Langevitz P., Shoenfeld Y. The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. Isr Med Assoc J 2009, 11(September (9)):558-563.
17. Yanai H., Shimizu N., Nagasaki S., Mitani N., Okita K. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol 1999, 94(June (6)):1582-1586.
18. Babcock G.J., Decker L.L., Volk M., Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 1998, 9(September (3)):395-404.
19. Spieker T., Herbst H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol 2000, 157(July (1)):51-57.
20. Gartner B., Preiksaitis J.K. EBV viral load detection in clinical virology. J Clin Virol 2010, 48(June (2)):82-90.
21. Weinstock D.M., Ambrossi G.G., Brennan C., Kiehn T.E., Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006, 37(March (6)):539-546.
22. Green M., Bueno J., Rowe D., Mazariegos G., Qu L., Abu-Almagd K., et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000, 70(August (4)):593-596.
23. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54(March (3)):692-701.
24. Fishman J.A., Emery V., Freeman R., Pascual M., Rostaing L., Schlitt H.J., et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 2007, 21(March-April (2)):149-158.
25. D'Ovidio V., Vernia P., Gentile G., Capobianchi A., Marcheggiano A., Viscido A., et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol 2008, 43(October (2)):180-183.
26. Guadalupe M., Reay E., Sankaran S., Prindiville T., Flamm J., McNeil A., et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003, 77(November (21)):11708-11717.
27. Kimura H., Morita M., Yabuta Y., Kuzushima K., Kato K., Kojima S., et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999, 37(January (1)):132-136.
28. Aalto S.M., Juvonen E., Tarkkanen J., Volin L., Ruutu T., Mattila P.S., et al. Lymphoproliferative disease after allogeneic stem cell transplantation-pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum. J Clin Virol 2003, 28(December (3)):275-283.
29. Sankaran S., Guadalupe M., Reay E., George M.D., Flamm J., Prindiville T., et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A 2005, 102(July (28)):9860-9865.
30. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104(February (2)):465-483. quiz 464, 484.
31. Lavagna A., Bergallo M., Daperno M., Sostegni R., Costa C., Leto R., et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007, 13(July (7)):896-902.
32. Santisteban M, Reynolds C, Barr Fritcher EG, Frost MH, Vierkant RA, Anderson SS, et al. Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat;121(June (2)):431-7.
33. D'Errico A., Garbisa S., Liotta L.A., Castronovo V., Stetler-Stevenson W.G., Grigioni W.F. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol 1991, 4(March (2)):239-246.
34. Hwang J.M., Varma M.G. Surgery for inflammatory bowel disease. World J Gastroenterol 2008, 14(May (17)):2678-2690.
35. Taoka K., Nannya Y., Yamamoto G., Sakatani T., Ota S., Fukayama M., et al. Progressive transition of Epstein-Barr virus associated lymphoproliferative disease subtypes with the development of lung cancer. Am J Hematol 2009, 84(September (9)):600-603.
36. Pietersma F., Piriou E., van Baarle D Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk Lymphoma 2008, 49(June (6)):1028-1041.
37. Cruchley A.T., Williams D.M., Niedobitek G., Young L.S. Epstein-Barr virus: biology and disease. Oral Dis 1997, 3(May (Suppl. 1)):S156-S163.
38. Tanner J.E., Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001, 3(June (2)):60-69.